Shire, New River Submit NDA For Amphetamine Prodrug NRP104
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms say lower abuse liability is potential advantage over other stimulant attention deficit/hyperactivity disorder treatments.
You may also be interested in...
Shire Anticipates Vyvanse Approval In “Next Month Or Two”
The firm is considering a marketing partner and aims to replace its ADHD treatment Adderall XR with Vyvanse.
Shire Anticipates Vyvanse Approval In “Next Month Or Two”
The firm is considering a marketing partner and aims to replace its ADHD treatment Adderall XR with Vyvanse.
Shire Settlement With Barr Permits Generic Adderall XR Entry In 2009
Questions over whether the deal will pass FTC muster demonstrate how jittery industry is becoming following a criminal probe into a Sanofi/Bristol agreement.